US Court Signs Off $70m Glenmark, Merck Settlement In Zetia ‘Pay-For-Delay’ Case
Indian Firm Announced Total Proposed Bill Of $87.5m Earlier This Year With Three Classes
Executive Summary
Months after signing off on claims from two other sets of plaintiffs, a US district court in Virginia has approved a settlement agreement with a third class to put to bed antitrust claims that Glenmark and Merck & Co conspired illegally to delay generic competition to Merck’s Zetia blockbuster.